Mutations in CRBN and other cereblon pathway genes are infrequently associated with acquired resistance to immunomodulatory drugs.
作者信息
Jones J R, Barber A, Le Bihan Y-V, Weinhold N, Ashby C, Walker B A, Wardell C P, Wang H, Kaiser M F, Jackson G H, Davies F E, Chopra R, Morgan G J, Pawlyn C
机构信息
The Institute of Cancer Research, London, UK.
Brighton and Sussex Medical School, Brighton, UK.
出版信息
Leukemia. 2021 Oct;35(10):3017-3020. doi: 10.1038/s41375-021-01373-4. Epub 2021 Aug 9.
Abstract
摘要
相似文献
1
Mutations in CRBN and other cereblon pathway genes are infrequently associated with acquired resistance to immunomodulatory drugs.
Leukemia. 2021 Oct;35(10):3017-3020. doi: 10.1038/s41375-021-01373-4. Epub 2021 Aug 9.
2
Evaluating the impact of CRBN mutations on response to immunomodulatory drugs and novel cereblon E3 ligase modulators in myeloma.
Blood. 2025 May 29;145(22):2630-2644. doi: 10.1182/blood.2024025861.
3
Cereblon enhancer methylation and IMiD resistance in multiple myeloma.
Blood. 2021 Nov 4;138(18):1721-1726. doi: 10.1182/blood.2020010452.
4
Resistance to immunomodulatory drugs in multiple myeloma: the cereblon pathway and beyond.
Haematologica. 2025 May 1;110(5):1074-1091. doi: 10.3324/haematol.2024.285636. Epub 2024 Nov 21.
5
The clinical significance of cereblon expression in multiple myeloma.
Leuk Res. 2014 Jan;38(1):23-8. doi: 10.1016/j.leukres.2013.08.015. Epub 2013 Sep 5.
6
Expression, mutation, and methylation of cereblon-pathway genes at pre- and post-lenalidomide treatment in multiple myeloma.
Cancer Sci. 2020 Apr;111(4):1333-1343. doi: 10.1111/cas.14352. Epub 2020 Mar 12.
7
Expression of CRBN, IKZF1, and IKZF3 does not predict lenalidomide sensitivity and mutations in the cereblon pathway are infrequent in multiple myeloma.
Leuk Lymphoma. 2019 Jan;60(1):180-188. doi: 10.1080/10428194.2018.1466290. Epub 2018 May 2.
8
Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma.
Blood. 2021 Jan 14;137(2):232-237. doi: 10.1182/blood.2020007081.
9
Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.
Blood. 2011 Nov 3;118(18):4771-9. doi: 10.1182/blood-2011-05-356063. Epub 2011 Aug 22.
10
IKZF1/3 and CRL4 E3 ubiquitin ligase mutations and resistance to immunomodulatory drugs in multiple myeloma.
Haematologica. 2020 May;105(5):e237-e241. doi: 10.3324/haematol.2019.217943. Epub 2019 Sep 26.
引用本文的文献
1
Resistance to immunomodulatory drugs in multiple myeloma: the cereblon pathway and beyond.
Haematologica. 2025 May 1;110(5):1074-1091. doi: 10.3324/haematol.2024.285636. Epub 2024 Nov 21.
2
IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma.
Cancer Cell. 2024 Jul 8;42(7):1185-1201.e14. doi: 10.1016/j.ccell.2024.05.026. Epub 2024 Jun 20.
3
Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma.
Blood Cancer Discov. 2024 Jan 8;5(1):34-55. doi: 10.1158/2643-3230.BCD-23-0062.
4
Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance.
Nat Commun. 2023 Sep 20;14(1):5825. doi: 10.1038/s41467-023-41562-6.
5
Advances in the molecular characterization of multiple myeloma and mechanism of therapeutic resistance.
Front Oncol. 2022 Oct 27;12:1020011. doi: 10.3389/fonc.2022.1020011. eCollection 2022.
6
CRL4 E3 Ligase Complex as a Therapeutic Target in Multiple Myeloma.
Cancers (Basel). 2022 Sep 16;14(18):4492. doi: 10.3390/cancers14184492.
Zotero 插件